Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.5552W HIGH $18.67
Volume
58.21 K
Value Traded
126.11 K
Short % Float
3.17%
Days to Cover
1.7
-16.92%Week
-19.2%1 Month
-30.77%3 Month
-62.41%6 Month
-99.01%5 Year
-67.86%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
15.76 M
EPS (TTM)
-2.95
P/E Ratio
-
Ent. Value
11.46 M
Total Shares
9.50 M
Float Shares
8.80 M
Insiders
7.30%
Institutions
24.10%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MODD Catalyst Timeline
Dated clinical, regulatory and corporate events for Modular Medical, Inc.
Past FDA Catalysts and PDUFA Decisions
How MODD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Modular Medical, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every MODD program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Vos Ellen O'ConnorDirector | Grant/Award | 250 250 held | $0.00 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MODD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.1 % | 447.54 K | 639.53 K | -9.97% ( -70.83 K) |
MODD Institutional Ownership Trends
MODD Short Interest
Shares sold short, counted twice a month.
3.17%
Short % of Float
of tradable shares sold short
279.4K
Shares Sold Short
-28.3% vs prior count
1.7 Low
Days to Cover
trading days of normal volume to buy every short share back
167.8K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MODD ranks across every disease it competes in
Competitive Position is a premium feature
See how MODD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMODD News
-MODD
Oct 27, 2026▲ +0.6%today
Modular Medical Announces Positive Notified Body Decision on ISO 13485:2016 Certification
Modular Medical announced a positive decision for ISO 13485:2016 certification, a key step toward CE Mark submission for its Pivot tubeless patch pump. The company aims for CE Mark approval in 2027, which would enable commercial distribution in the EU. This certification confirms the quality management system meets international standards.
Read more →-MODD
Oct 15, 2026▲ +10.8%on this news
Modular Medical Launches Digital Learning Tools to Support Adoption of Pivot Insulin Delivery System
Modular Medical has launched two digital education tools to aid diabetes patients in adopting the Pivot insulin delivery system. Developed with Relevate Health Games, these game-based resources aim to improve patient confidence and familiarity with insulin pump therapy. The tools are designed to complement formal training and assist healthcare providers in evaluating patient readiness.
Read more →-MODD
Oct 7, 2026Modular Medical to Present at the Webull Emerging & Innovative Companies Webinar on October 14th
Modular Medical, Inc. announced that CEO Jeb Besser will present at the Webull Emerging & Innovative Companies Webinar on October 14, 2026. The company is preparing for the commercial launch of its Pivot™ tubeless patch pump, which is designed to simplify insulin delivery for diabetes patients. The presentation will provide insights into the company's innovative technologies.
Read more →-MODD
Sep 8, 2026▼ -23.4%on this news
Modular Medical to Participate in the iAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 on September 15-16, 2026
Modular Medical, Inc. will participate in the iAccess Alpha Virtual Best Ideas Fall Investment Conference on September 15-16, 2026. CEO Jeb Besser will present and hold one-on-one meetings to discuss the company's upcoming launch of the Pivot™ tubeless patch pump. This device is designed to enhance insulin delivery for diabetes patients.
Read more →-MODD
Sep 4, 2026▲ +7.6%on this news· ran to -23% by day 3shared move
Modular Medical Announces Contract with National U.S. Pharmacy Benefit Manager, Expanding Access to Pivot Tubeless Patch Pump
Modular Medical has announced a contract with a national U.S. pharmacy benefit manager, enhancing access to its Pivot tubeless patch pump for diabetes management. This partnership is expected to broaden patient access and validate the product's effectiveness. The Pivot pump aims to simplify insulin delivery for individuals requiring intensive therapy.
Read more →-MODD
Sep 4, 2026▲ +7.6%on this news· ran to -23% by day 3shared move
Registration is Now Open for Tribe Public's CEO Presentation and Q&A Webinar Event Titled ''The Road To Revenue: Modular Medical's Strategy For Launching Pivot'' Featuring Modular Medical CEO - Friday, September 4, 2026
Modular Medical, Inc. has announced a webinar featuring CEO Jeb Besser to discuss the launch strategy for its new Pivot tubeless patch pump. The event, titled 'The Road To Revenue,' is scheduled for September 4, 2026, and aims to provide insights into the company's innovative insulin delivery technology. Participants can register for free and submit questions for the CEO during the event.
Read more →-MODD
Sep 3, 2026Modular Medical Announces FDA Clearance of Pivot Tubeless Insulin Patch Pump Enhancements
Modular Medical has received FDA clearance for software enhancements to its Pivot tubeless insulin patch pump. These upgrades aim to improve user flexibility and customization in bolus dosing, along with an enhanced user interface. The company anticipates launching the upgraded system in the fourth quarter of 2026, marking a significant step in its insulin delivery technology.
Read more →-MODD
Apr 20, 2026▼ -7.7%on this news
Modular Medical Announces Pricing of $3.4 Million Registered Direct Offering of Common Stock
Modular Medical, Inc. has announced the pricing of a registered direct offering of 750,000 shares of common stock at $4.50 each, expected to generate around $3.4 million. The offering is set to close on or about April 21, 2026, pending customary closing conditions. Maxim Group LLC is the sole placement agent for this offering.
Read more →-MODD
Apr 16, 2026Modular Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
Modular Medical, Inc. has announced that it has successfully regained compliance with the Nasdaq Capital Market's minimum bid price requirement. As of April 14, 2026, the company's common stock has maintained a closing bid price exceeding $1.00 for 10 consecutive trading days. Nasdaq has confirmed that the matter is now closed. Modular Medical aims to innovate in insulin delivery technology, making it both affordable and user-friendly.
Read more →-MODD
Mar 26, 2026▼ -7.1%on this news
Modular Medical Announces 1-for-30 Reverse Stock
Modular Medical, Inc. has announced a 1-for-30 reverse stock split of its common stock, effective March 31, 2026. This decision was made to satisfy Nasdaq's minimum bid price requirement of $1.00 per share, following approval from shareholders at the fiscal 2026 Annual Meeting. Post-split, approximately 4.66 million shares will remain outstanding. The change is aimed at improving the company's financial standing and market perception. Shareholders will receive cash for any fractional shares resulting from the split.
Read more →-MODD
Mar 3, 2026▲ +7%on this news· ran to +27% by day 3
Modular Medical Announces $12.0 Million Public Offering Priced at a Premium to Market
Modular Medical, Inc. has announced a $12.0 million public offering priced at $0.1762 per share, aimed at new and existing investors. The offering includes 68,098,000 shares and warrants exercisable immediately. The expected gross proceeds may enhance the company's financial position as it prepares for the closing, scheduled around March 4, 2026. Maxim Group LLC serves as the sole placement agent for this offering.
Read more →-MODD
Feb 5, 2026Modular Medical Achieves Key Manufacturing Milestone for Pivot Tubeless Insulin Patch Pump
Modular Medical has commenced production of validation lots for its Pivot tubeless insulin patch pump, aiming for a Q1 2026 launch pending FDA clearance. The Pivot system targets adults with diabetes who are reluctant to switch from multiple daily injections due to cost and complexity. This milestone is expected to enhance the company's scalability and market position in the growing diabetes tech sector.
Read more →-MODD
Jan 1, 2026▲ +5.7%on this news· ran to +22% by day 3
Modular Medical Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Rule
Modular Medical, Inc. has been granted a 180-day extension by Nasdaq to comply with the minimum bid price requirement. The company must achieve a closing bid price of $1.00 per share for 10 consecutive business days by June 29, 2026, to regain compliance. If unsuccessful, it risks delisting but can appeal any decision made by Nasdaq.
Read more →-MODD
Dec 9, 2025Modular Medical Announces Proposed Public Offering
Modular Medical, Inc. has announced a proposed public offering of its common stock and warrants to expand its operations. The offering is targeted at adult diabetics and is expected to improve access to innovative insulin delivery technology. While the company has initiated this offering to potentially enhance funding and growth, it also noted the uncertainties surrounding its completion and market conditions. The offering is backed by Newbridge Securities Corporation as the sole bookrunner and follows a previously effective registration statement.
Read more →-MODD
May 28, 2025Modular Medical Appoints Industry Veteran Jeff Goldberg to Board
Modular Medical has announced the appointment of Jeff Goldberg to its Board of Directors. Goldberg, an established industry veteran, brings significant experience in healthcare and medical devices, particularly in developing generic insulin. His leadership is anticipated to support Modular Medical's goals of simplifying insulin delivery and enhancing diabetes care. The company aims to provide affordable and effective insulin delivery solutions, with Goldberg playing a crucial role in this vision.
Read more →-MODD
Sep 4, 2024▲ +6.4%on this news· ran to +23% by day 3
Modular Medical Announces FDA Clearance of the MODD1 Insulin Pump MODD1 is a patch pump for ALL adults with Type 1 and Type 2 diabetes Designed to be simpler and more affordable to expand access to diabetes technology fo
Modular Medical, Inc. has announced that the U.S. FDA has cleared its MODD1 insulin pump for marketing and sale in the United States. The company is focusing on making diabetes care more accessible and affordable, particularly for underserved communities. With commercial manufacturing nearly complete, the MODD1 pump is expected to be available for consumers in early 2025. The leadership expresses gratitude to employees and shareholders, emphasizing their commitment to improving diabetes care.
Read more →-MODD
Feb 15, 2024▲ +10.1%on this news· ran to +55% by day 3
Modular Medical Announces Proposed Public Offering San Diego
Modular Medical, Inc. announced a proposed public offering of its common stock to support its development of next-generation insulin delivery technology. The offering includes a 30-day option for the underwriter to purchase additional shares, but it remains subject to market conditions. The company, led by experienced professionals in medical devices, aims to improve access to insulin delivery systems, although uncertainty exists regarding the completion and terms of the offering. This step is crucial for financing further product development against various market risks.
Read more →-MODD
Jan 19, 2024▲ +5.9%on this news
Modular Medical Announces 510(k) Submission of MODD1 Insulin Pump
Modular Medical has announced the submission of its MODD1 insulin pump for 510(k) clearance to the FDA, marking a significant step in its product development. The company is focused on creating a user-friendly and affordable device to enhance diabetes management. The pump's design aims to attract users who have been deterred by the complexity and cost of existing insulin pumps. Additionally, Modular Medical plans to pursue UKCA mark clearance while preparing for market launch.
Read more →-MODD
Dec 26, 2023▲ +5.8%on this news
Investor Presentation . NASDAQ:MODD 2 | Forward Looking Statements, Other Disclaimers . This presentation includes forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended;
Modular Medical, a development stage medical device company, is presenting its innovative insulin delivery system, MODD1, aimed at expanding access for diabetes management. The company plans to submit for FDA approval in January 2024 and targets a $3 billion market. The presentation highlights both the potential benefits of their product and the inherent risks associated with their forward-looking statements, particularly in relation to regulatory compliance and market acceptance. The company acknowledges the complexities and high costs of existing insulin pump systems as significant barriers to adoption among patients.
Read more →About Modular Medical, Inc.
Headquarters10740 THORNMINT ROAD, SAN DIEGO, CA, 92127
BIOPHARMAWATCH ELITE PLUS
Trade the next MODD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime